11. 重症筋無力症 [臨床試験数:226,薬物数:172(DrugBank:45),標的遺伝子数:43,標的パスウェイ数:118

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04182984November 4, 201926/11/2019TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyTheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world StudyOcular Myasthenia GravisDrug: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)Tang-Du HospitalNULLRecruiting18 Years75 YearsAll200China
2JPRN-UMIN0000150192014/09/0202/09/2014Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG Myasthenia gravisTacrolimus and IVIGKansai medical universityNULLRecruitingNot applicableNot applicableMale and Female20Not appl1cableJapan
3JPRN-UMIN0000076712012/04/0109/04/2012Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients Myasthenia gravisAdministration of prednisolone 35 mg/day with tacrolimus 3mg a day
Administration of prednisolone 50 mg/day
Department of Neurology, Chiba University Graduate School of MedicineNULLRecruiting50years-oldNot applicableMale and Female40Not appl1cableJapan
4JPRN-UMIN0000076792012/04/0109/04/2012Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients Myasthenia gravisAdministration of tacrolimus 3 mg/day
Administration of prednisolone 5 mg/day
anticholinesterases
Department of Neurology, Chiba University Graduate School of MedicineNULLRecruiting20years-oldNot applicableMale and Female60Not selectedJapan
5NCT01325571March 201116/3/2011A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia GravisA Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid TherapyMyasthenia GravisDrug: Tacrolimus capsule;Drug: PlaceboAstellas Pharma IncAstellas Pharma China, Inc.Completed18 Years70 YearsBoth83Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00309088April 200629/3/2006FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) PatientsFK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis PatientsMyasthenia GravisDrug: tacrolimus;Drug: placeboAstellas Pharma IncNULLCompleted16 Years64 YearsBoth80Phase 3Japan
7NCT00309101February 200629/3/2006An Open Study for Steroid Resistant, Non-Thymectomized MG PatientsFK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG PatientsMyasthenia GravisDrug: tacrolimusAstellas Pharma IncNULLCompleted16 Years64 YearsBoth11Phase 3Japan